Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Metsera Inc. raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement . It had offered 17.2 million shares for $15 to $17 each.

Metsera raised $275 million in its IPO ... Also on Thursday, Maze Therapeutics priced an upsized IPO at $16 a share, in the middle of a marketed range, according to a statement.

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

In its IPO prospectus, Maze has highlighted tariffs as a potential ... Separately, weight-loss drug developer Metsera, also making its debut on Friday, raised $275 million after pricing its ...

(Bloomberg) -- Metsera Inc. is seeking to raise $292 ... The biotech firm joins a group of health care companies advancing their IPO plans. Maze Theraupeutics Inc., which develops precision ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Metsera expects its cash will last into 2027. Two other life science companies went public this past week. Here’s a look at those IPOs: Maze Therapeutics Finds Way to $140M IPO for Chronic ...

Metsera Inc. raised $275 million in ... Also on Thursday, Maze Therapeutics Inc. priced an upsized IPO at $16 a share, in the middle of a marketed range, according to a statement.